MIT engineers an anti-cancer smart bomb

Jul 27, 2005

Imagine a cancer drug that can burrow into a tumor, seal the exits and detonate a lethal dose of anti-cancer toxins, all while leaving healthy cells unscathed. MIT researchers have designed a nanoparticle to do just that.


The dual-chamber, double-acting, drug-packing "nanocell" proved effective and safe, with prolonged survival, against two distinct forms of cancers-melanoma and Lewis lung cancer-in mice.

The work will be reported in the July 28 issue of Nature, with an accompanying commentary.

"We brought together three elements: cancer biology, pharmacology and engineering," said Ram Sasisekharan, a professor in MIT's Biological Engineering Division and leader of the research team.

"The fundamental challenges in cancer chemotherapy are its toxicity to healthy cells and drug resistance by cancer cells," Sasisekharan said. "So cancer researchers were excited about anti-angiogenesis," the theory that cutting off the blood supply can starve tumors to death. That strategy can backfire, however, because it also starves tumor cells of oxygen, prompting them to create new blood vessels and instigate metastasis and other self-survival activities.

The next obvious solution would be combining chemotherapy and anti-angiogenesis-dropping the bombs while cutting the supply lines. But combination therapy confronted an inherent engineering problem. "You can't deliver chemotherapy to tumors if you have destroyed the vessels that take it there," Sasisekharan said. Also, the two drugs behave differently and are delivered on different schedules: anti-angiogenics over a prolonged period and chemotherapy in cycles.

"We designed the nanocell keeping these practical problems in mind," he said. Using ready-made drugs and materials, "we created a balloon within a balloon, resembling an actual cell," explains Shiladitya Sengupta, a postdoctoral associate in Sasisekharan's laboratory.

In addition to Sasisekharan and Sengupta, the co-authors are David Eavarone, Ishan Capila and Ganlin Zhao of MIT's Biological Engineering Division; Nicki Watson of the Whitehead Institute for Biomedical Research; and Tanyel Kiziltepe of MIT's Department of Chemistry.

The team loaded the outer membrane of the nanocell with an anti-angiogenic drug and the inner balloon with chemotherapy agents. A "stealth" surface chemistry allows the nanocells to evade the immune system, while their size (200 nanometers) makes them preferentially taken into the tumor. They are small enough to pass through tumor vessels, but too large for the pores of normal vessels.

Once the nanocell is inside the tumor, its outer membrane disintegrates, rapidly deploying the anti-angiogenic drug. The blood vessels feeding the tumor then collapse, trapping the loaded nanoparticle in the tumor, where it slowly releases the chemotherapy.

The team tested this model in mice. The double-loaded nanocell shrank the tumor, stopped angiogenesis and avoided systemic toxicity much better than other treatment and delivery variations.

But it is patient survival and quality of life that really inspire this research, Sasisekharan said. Eighty percent of the nanocell mice survived beyond 65 days, while mice treated with the best current therapy survived 30 days. Untreated animals died at 20.

"It's an elegant technique for attacking the two compartments of a tumor, its vascular system and the cancer cells," said Judah Folkman of Children's Hospital Boston. "This is a very neat approach to drug delivery," said MIT Institute Professor Robert Langer.

The nanocell worked better against melanoma than lung cancer, indicating the need to tweak the design for different cancers. "This model enables us to rationally and systematically evaluate drug combinations and loading mechanisms," says Sasisekharan. "It's not going to stop here. We want to build on this concept."

Source: Massachusetts Institute of Technology

Explore further: Local education politics 'far from dead'

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Local education politics 'far from dead'

12 hours ago

Teach for America, known for recruiting teachers, is also setting its sights on capturing school board seats across the nation. Surprisingly, however, political candidates from the program aren't just pushing ...

First grade reading suffers in segregated schools

12 hours ago

A groundbreaking study from the Frank Porter Graham Child Development Institute (FPG) has found that African-American students in first grade experience smaller gains in reading when they attend segregated schools—but the ...

Violent aftermath for the warriors at Alken Enge

13 hours ago

Denmark attracted international attention in 2012 when archaeological excavations revealed the bones of an entire army, whose warriors had been thrown into the bogs near the Alken Enge wetlands in East Jutland ...

Why aren't consumers buying remanufactured products?

15 hours ago

Firms looking to increase market share of remanufactured consumer products will have to overcome a big barrier to do so, according to a recent study from the Penn State Smeal College of Business. Findings from faculty members ...

Expecting to teach enhances learning, recall

15 hours ago

People learn better and recall more when given the impression that they will soon have to teach newly acquired material to someone else, suggests new research from Washington University in St. Louis.

User comments : 0